Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

Stock Information for BioSig Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioSig Technologies Inc.

BioSig Engages Consulting Firm for Business Model Strategies
BioSig Announces Reduction of its Workforce
BioSig's PURE EP(TM) Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
BioSig Announces Reverse Stock Split
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.